Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

37.40
-0.5100-1.35%
Post-market: 37.430.0299+0.08%18:59 EDT
Volume:12.64M
Turnover:475.14M
Market Cap:166.99B
PE:9.34
High:37.97
Open:37.80
Low:37.37
Close:37.91
52wk High:64.16
52wk Low:35.12
Shares:4.47B
Float Shares:3.19B
Volume Ratio:0.87
T/O Rate:0.40%
Dividend:1.72
Dividend Rate:4.60%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:5.13
PE(LYR):10.33

Loading ...

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Yesterday

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Yesterday

Moderately bullish activity in Novo Nordisk with shares down 1.06%

TIPRANKS
·
Yesterday

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

TIPRANKS
·
Yesterday

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

TIPRANKS
·
Yesterday

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Yesterday

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Novo Nordisk announces new data on CagriSema

TIPRANKS
·
Sep 30

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Sep 30

Novo Says Ozempic Cuts Risk of Major Cardiovascular Events

Reuters
·
Sep 29

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

TIPRANKS
·
Sep 29

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Dow Jones
·
Sep 29

Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project

Stock News
·
Sep 29

Option traders moderately bearish in Novo Nordisk with shares down 0.22%

TIPRANKS
·
Sep 29

Novo Nordisk A/S Series B Stock Falls Monday, Outperforms Market

Dow Jones
·
Sep 29

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28